Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 09, 2023

BUY
$5.07 - $8.44 $3.73 Million - $6.2 Million
734,803 Added 523.84%
875,075 $4.77 Million
Q2 2023

Aug 10, 2023

BUY
$6.19 - $8.78 $693,700 - $983,957
112,068 Added 397.35%
140,272 $941,000
Q1 2023

May 11, 2023

SELL
$7.8 - $10.11 $489,941 - $635,039
-62,813 Reduced 69.01%
28,204 $249,000
Q4 2022

Feb 13, 2023

SELL
$6.26 - $9.34 $1.59 Million - $2.38 Million
-254,547 Reduced 73.66%
91,017 $695,000
Q3 2022

Nov 10, 2022

BUY
$6.5 - $12.67 $2 Million - $3.91 Million
308,252 Added 826.15%
345,564 $2.46 Million
Q2 2022

Aug 19, 2022

SELL
$6.4 - $14.73 $1.08 Million - $2.5 Million
-169,454 Reduced 81.95%
37,312 $302,000
Q1 2022

May 13, 2022

BUY
$10.12 - $28.9 $1.96 Million - $5.6 Million
193,889 Added 1505.7%
206,766 $2.87 Million
Q4 2021

Feb 11, 2022

BUY
$25.17 - $36.85 $324,114 - $474,517
12,877 New
12,877 $361,000
Q1 2021

May 17, 2021

SELL
$37.26 - $67.74 $404,010 - $734,504
-10,843 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$45.01 - $65.47 $57,207 - $83,212
-1,271 Reduced 10.49%
10,843 $641,000
Q3 2020

Nov 16, 2020

SELL
$35.79 - $48.81 $2.59 Million - $3.53 Million
-72,402 Reduced 85.67%
12,114 $589,000
Q2 2020

Aug 14, 2020

BUY
$24.95 - $48.38 $2.11 Million - $4.09 Million
84,516 New
84,516 $4.09 Million
Q4 2019

Feb 14, 2020

SELL
$24.56 - $32.8 $292,460 - $390,582
-11,908 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$30.31 - $53.51 $2.13 Million - $3.76 Million
-70,225 Reduced 85.5%
11,908 $368,000
Q2 2019

Aug 14, 2019

BUY
$40.3 - $48.3 $3.31 Million - $3.97 Million
82,133 New
82,133 $3.97 Million

Others Institutions Holding ADPT

About Adaptive Biotechnologies Corp


  • Ticker ADPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 142,872,992
  • Market Cap $849M
  • Description
  • Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...
More about ADPT
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.